Hg makes further investment in Evaluate
Hg has secured a majority stake in portfolio company Evaluate following an additional investment in the pharmaceuticals analytics business.
Hg originally invested in Evaluate in November 2016 for a deal value of £40m, according to Unquote Data. The firm invested from its Hg Mercury Fund, which closed on £380m in March 2013. Hg Capital Trust, the listed vehicle that invests in Hg's deals alongside the firm, also took part in the deal, investing £3.7m of capital.
The firm is currently investing from its Hg Mercury 3 vehicle, which held a first close on €1bn in March 2020.
Hg Capital Trust has invested approximately £8.1m in this latest deal alongside other institutional clients of Hg.
As part of the transaction, Jonathan de Pass, founder of Evaluate, will remain a significant shareholder and will continue to act as a director on the board.
In addition, Sati Sian has been appointed as chair. He was previously CEO for Allocate Software between 2015 and 2018.
Company
Founded in 1996, London-headquartered Evaluate is a provider of commercial intelligence and predictive analytics for the pharmaceutical industry. For the year ending on 30 September 2019, the company reported a turnover £30.8m.
People
Hg - David Issott (partner).
Evaluate - Jonathan de Pass (founder).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds









